logo.png
Lenabasum Open-Label Extension Data to be Presented at EULAR 2019 Continue to Show a Favorable Safety Profile and Improvement in Efficacy Outcomes in Systemic Sclerosis and Dermatomyositis Phase 2 Studies
June 12, 2019 08:05 ET | Corbus Pharmaceuticals Holdings, Inc.
ACR CRISS score remains ≥ 0.95 (95%) at 21 months in systemic sclerosis open-label extension (OLE) studyCDASI activity score reaches -21.8 points at 16 months in dermatomyositis OLE study81% systemic...
logo.png
Corbus Pharmaceuticals Reports 2019 First Quarter Financial Results and Provides Clinical Updates
May 09, 2019 07:00 ET | Corbus Pharmaceuticals Holdings, Inc.
Continued progress made in four ongoing clinical studies as lenabasum advances towards 2020 data readouts in lead indications systemic sclerosis and cystic fibrosis Second clinical candidate...
logo.png
Corbus Pharmaceuticals Completes Enrollment of RESOLVE-1 Phase 3 Study of Lenabasum for Treatment of Systemic Sclerosis
May 02, 2019 08:05 ET | Corbus Pharmaceuticals Holdings, Inc.
Company anticipates topline results of RESOLVE-1 study in the summer of 2020Systemic sclerosis (SSc) is a chronic, rare systemic autoimmune disease affecting approximately 200,000 people in the U.S.,...
logo.png
Corbus Pharmaceuticals Announces Strategic Collaboration with Kaken Pharmaceutical Co., Ltd. to Develop and Commercialize Lenabasum in Japan for Systemic Sclerosis and Dermatomyositis
January 03, 2019 10:01 ET | Corbus Pharmaceuticals Holdings, Inc.
Collaboration in-line with Corbus vision to become the global leader in the treatment of inflammatory and fibrotic diseases by targeting the endocannabinoid systemAdvances strategy to partner...
CRBP-300-196.png
Corbus Pharmaceuticals Announces Issuance of Composition of Matter Patent Related to Lenabasum
December 18, 2018 08:46 ET | Corbus Pharmaceuticals Holdings, Inc.
Company’s vision is to become the leader in the treatment of inflammatory and fibrotic diseases by targeting the endocannabinoid systemLenabasum in late-stage clinical studies in three orphan...
CRBP-300-196.png
Corbus Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Business Update
November 08, 2018 07:00 ET | Corbus Pharmaceuticals Holdings, Inc.
Licensed Jenrin Discovery’s extensive library of small molecules targeting the endocannabinoid system (ECS) positioning Corbus with the leading pipeline focused on treating inflammatory and fibrotic...
CRBP-300-196.png
Corbus Pharmaceuticals Presents Lenabasum Long-Term Open-Label Clinical Data Showing Maintenance of Favorable Safety Profile and Further Improvement in Multiple Efficacy Endpoints in Systemic Sclerosis and Dermatomyositis Phase 2 Studies
October 22, 2018 08:00 ET | Corbus Pharmaceuticals Holdings, Inc.
Lenabasum is a first-in-class novel, synthetic oral cannabinoid designed to treat rare, serious autoimmune diseasesFavorable safety and tolerability profiles maintained with long-term chronic...
CRBP-300-196.png
Corbus Pharmaceuticals Announces Patent Issuance Covering Use of Lenabasum for the Treatment of Fibrotic Diseases Providing Exclusivity to 2034
October 03, 2018 09:00 ET | Corbus Pharmaceuticals Holdings, Inc.
Company’s vision is to become the leader in the treatment of inflammatory and fibrotic diseases by targeting the endocannabinoid systemIntellectual property around pipeline targeting endocannabinoid...
CRBP-300-196.png
Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences in October
September 26, 2018 08:00 ET | Corbus Pharmaceuticals Holdings, Inc.
– Cantor Global Healthcare Conference presentation with live audio webcast on Monday, October 1st at 2:55 PM ET – – Leerink Partners Roundtable Series: Rare Disease & Oncology fireside chat...
CRBP-300-196.png
Corbus Pharmaceuticals Reports 2018 Second Quarter Financial Results and Provides Business Update
August 08, 2018 09:00 ET | Corbus Pharmaceuticals Holdings, Inc.
Lenabasum has reached Phase 3 clinical stage in two orphan autoimmune indications: systemic sclerosis and dermatomyositis, affecting up to 200,000 patients in the USA, EU and JapanRecent long-term...